FDA approves esketamine treatment for MDD, suicidal ideation
Valerie A. Canady
Abstract
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.
Topics & Concepts
Suicidal ideationFood and drug administrationMajor depressive disorderMedicineDepression (economics)DrugPsychiatryPharmacologyPoison controlEmergency medicineSuicide preventionMacroeconomicsCognitionEconomicsTreatment of Major Depression